{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-dateTabled=2019-07-16&houseId=1&max-ddpModified.=2019-07-17T14%3A45%3A45.925Z&hansardHeading=HIV+Infection%3A+Drugs", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-dateTabled=2019-07-16&houseId=1&max-ddpModified.=2019-07-17T14%3A45%3A45.925Z&hansardHeading=HIV+Infection%3A+Drugs", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-dateTabled=2019-07-16&houseId=1&max-ddpModified.=2019-07-17T14%3A45%3A45.925Z&_metadata=all&hansardHeading=HIV+Infection%3A+Drugs", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-dateTabled=2019-07-16&houseId=1&max-ddpModified.=2019-07-17T14%3A45%3A45.925Z&hansardHeading=HIV+Infection%3A+Drugs", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-dateTabled=2019-07-16&houseId=1&max-ddpModified.=2019-07-17T14%3A45%3A45.925Z&hansardHeading=HIV+Infection%3A+Drugs", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-dateTabled=2019-07-16&houseId=1&max-ddpModified.=2019-07-17T14%3A45%3A45.925Z&hansardHeading=HIV+Infection%3A+Drugs", "items" : [{"_about" : "http://data.parliament.uk/resources/1139193", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1139193/answer", "answerText" : {"_value" : "<p>My Rt. hon. Friend the Secretary of State for Health and Social Care has had numerous discussions with cabinet ministers to discuss a range of topics in advance of the Spending Review. Public health funding for 2020 onwards, including for HIV and sexual health services, will be considered carefully in the next Spending Review, in the light of the available evidence.<\/p><p>It is for individual local authorities to decide their spending priorities based on an assessment of local need, including sexual health services, taking account of their statutory duties. Participation in the pre-exposure prophylaxis Impact Trial is on a voluntary basis.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-07-22", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "277793"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-07-22T15:40:08.913Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions he is having with the Chancellor of the Exchequer on a long-term and sustainable funding package for the extension of PrEP trials.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4510", "label" : {"_value" : "Biography information for Helen Hayes"}
      }
      , "tablingMemberConstituency" : {"_value" : "Dulwich and West Norwood"}
      , "tablingMemberPrinted" : [{"_value" : "Helen Hayes"}
      ], "uin" : "277792"}
    , {"_about" : "http://data.parliament.uk/resources/1139194", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1139194/answer", "answerText" : {"_value" : "<p>My Rt. hon. Friend the Secretary of State for Health and Social Care has had numerous discussions with cabinet ministers to discuss a range of topics in advance of the Spending Review. Public health funding for 2020 onwards, including for HIV and sexual health services, will be considered carefully in the next Spending Review, in the light of the available evidence.<\/p><p>It is for individual local authorities to decide their spending priorities based on an assessment of local need, including sexual health services, taking account of their statutory duties. Participation in the pre-exposure prophylaxis Impact Trial is on a voluntary basis.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-07-22", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "277792"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-07-22T15:40:08.96Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions he has had with the Chancellor of the Exchequer on a small investment for public health budgets to increase the provision for PrEP trials.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4510", "label" : {"_value" : "Biography information for Helen Hayes"}
      }
      , "tablingMemberConstituency" : {"_value" : "Dulwich and West Norwood"}
      , "tablingMemberPrinted" : [{"_value" : "Helen Hayes"}
      ], "uin" : "277793"}
    , {"_about" : "http://data.parliament.uk/resources/1139333", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1139333/answer", "answerText" : {"_value" : "<p>Following my Rt. hon. Friend the Secretary of State for Health and Social Care\u2019s announcement on 30 January that the Pre-Exposure Prophylaxis (PrEP) Impact Trial would be expanded to 26,000 people, NHS England has committed to fund the PrEP drug and research costs of these additional places, in line with current arrangements.<\/p><p>Local authority and clinic participation in the trial is on a voluntary basis. Participation costs of local authorities are met from existing resource allocations.<\/p><p>The 36 month PrEP Impact Trial is scheduled to continue until autumn 2020. Work is underway to prepare for a seamless transition from the PrEP trial to future commissioning arrangements, which includes consideration of funding options.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "277798"}
        , {"_value" : "277799"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-07-23T16:42:07.197Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what additional funding his Department will allocate to the NHS to fund the expansion of the PrEP Impact trial.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4520", "label" : {"_value" : "Biography information for Matthew Pennycook"}
      }
      , "tablingMemberConstituency" : {"_value" : "Greenwich and Woolwich"}
      , "tablingMemberPrinted" : [{"_value" : "Matthew Pennycook"}
      ], "uin" : "277797"}
    , {"_about" : "http://data.parliament.uk/resources/1139335", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1139335/answer", "answerText" : {"_value" : "<p>Following my Rt. hon. Friend the Secretary of State for Health and Social Care\u2019s announcement on 30 January that the Pre-Exposure Prophylaxis (PrEP) Impact Trial would be expanded to 26,000 people, NHS England has committed to fund the PrEP drug and research costs of these additional places, in line with current arrangements.<\/p><p>Local authority and clinic participation in the trial is on a voluntary basis. Participation costs of local authorities are met from existing resource allocations.<\/p><p>The 36 month PrEP Impact Trial is scheduled to continue until autumn 2020. Work is underway to prepare for a seamless transition from the PrEP trial to future commissioning arrangements, which includes consideration of funding options.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "277797"}
        , {"_value" : "277798"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-07-23T16:42:07.28Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if it is his Department\u2019s policy that there should be continuous delivery of PrEP for participants after the conclusion of the PrEP Impact trial.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4520", "label" : {"_value" : "Biography information for Matthew Pennycook"}
      }
      , "tablingMemberConstituency" : {"_value" : "Greenwich and Woolwich"}
      , "tablingMemberPrinted" : [{"_value" : "Matthew Pennycook"}
      ], "uin" : "277799"}
    , {"_about" : "http://data.parliament.uk/resources/1139371", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1139371/answer", "answerText" : {"_value" : "<p>Women at high risk of contracting HIV are already eligible to participate in the Pre-Exposure Prophylaxis Impact Trial.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-07-23T16:43:55.213Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department plans to include women who are at risk of contracting HIV in the PrEP impact trial.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "277726"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 5, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}